Home > Insider Trading > Filing (0001415889-24-000818)

Filing Details

Accession Number:: 0001415889-24-000818
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2024-01-08 18:00:20
Reporting Period:: 2024-01-05

Accepted Time:: 2024-01-08 18:00:20
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1798749	Aerovate Therapeutics Inc.	AVTE	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1168060	Ralph Niven	C/O Aerovate Therapeutics, Inc. 930 Winter Street, Suite M-500 Waltham MA 02451	Chief Scientific Officer	No	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2024-01-05	1,400	$1.74	3,009	No	4	M	Direct
Common Stock	Acquisiton	2024-01-05	3,200	$2.14	6,209	No	4	M	Direct
Common Stock	Disposition	2024-01-05	2,126	$18.67	4,083	No	4	S	Direct
Common Stock	Disposition	2024-01-05	2,474	$19.57	1,609	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (Right to Buy)	Disposition	2024-01-05	900	$0.00	900	$1.74
Common Stock	Stock Option (Right to Buy)	Disposition	2024-01-05	500	$0.00	500	$1.74
Common Stock	Stock Option (Right to Buy)	Disposition	2024-01-05	500	$0.00	500	$2.14
Common Stock	Stock Option (Right to Buy)	Disposition	2024-01-05	1,200	$0.00	1,200	$2.14
Common Stock	Stock Option (Right to Buy)	Disposition	2024-01-05	1,500	$0.00	1,500	$2.14

Remaning Holdings	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
14,208	2030-09-03	No	4	M	Direct
9,588	2030-09-03	No	4	M	Direct
11,394	2031-04-01	No	4	M	Direct
36,108	2031-04-01	No	4	M	Direct
43,232	2031-04-01	No	4	M	Direct

Footnotes

This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 25, 2023.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $18.315 to $19.30, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $19.375 to $19.88, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request
A total of 24,108 shares subject to an employee stock option were granted on September 4, 2020, with 25% of this option vested on August 1, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter.
A total of 14,488 shares subject to an employee stock option were granted on September 4, 2020, with 25% of this option vested on June 1, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter.
A total of 16,294 shares subject to an employee stock option were granted on April 2, 2021, with options vesting in 48 equal monthly installments, with the first installment vested on May 2, 2021.
A total of 49,908 shares subject to an employee stock option were granted on April 2, 2021, with options vesting in 48 equal monthly installments, with the first installment vested on July 4, 2021.
A total of 59,732 shares subject to an employee stock option were granted on April 2, 2021, with options vesting in 48 equal monthly installments, with the first installment vested on July 4, 2021.